Lilly applies for Alzheimer's drug's US approval after trial

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details

Related Keywords

California , United States , Amsterdam , Noord Holland , Netherlands , San Francisco , New York , Eric Widera , Eisai Leqembi , Maria Carrillo , David Knopman , Alzheimer Association International Conference , Biogen Inc , Alzheimer Association , Drug Administration , University Of California , Eli Lilly Co , Eisai Co , Eli Lilly , Association International Conference , Mayo Clinic , Business And Commerce , Government Regulatory Actions , Business Regulation , Ealth And Wellness , Drug And Device Approval Process , Edical Conditions And Diseases , Drug Testing And Approval Process , Egulatory Drug Approval , Edicinal Drugs , Emerging Treatments , Medical And Pharmaceutical Regulation , Reatments And Therapies , Rading Impact Ice Codes Important Corporate Events , Ife And Society , Aging And The Elderly , Olitics And Government , Overnment Agencies Us , Food And Drug Administration , Department Of Health And Human Services , Government Regulation , Pharmaceuticals , Manufacturing , Manufactured Drugs , North America , Western Europe , Americas , Europe , The Netherlands , New York City ,